Acrivon Therapeutics Gets FDA's Breakthrough Designation for Cancer Assay
By Dean Seal
Acrivon Therapeutics said federal regulators have granted breakthrough device designation for its ACR-368 OncoSignature assay, which is being developed to identify ovarian cancer patients who may benefit from ACR-368 treatment.
The Watertown, Mass.-based company said the U.S. Food and Drug Administration's designation will help get patients and healthcare providers more timely access to its medical device by speeding up the development, assessment and review processes for premarket approval and marketing authorization.
Chief Executive Peter Blume-Jensen said the assay is being developed to predict tumor sensitivity to ACR-368 and used in ongoing clinical studies.
Breakthrough device designation is granted to devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions for which no approved alternative exists.
"We believe this designation is the first of its kind for such an assay, and represents yet another powerful validation of our [Acrivon Predictive Precision Proteomics] platform," Blume-Jensen said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 28, 2023 08:43 ET (13:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Uber Earnings: Network Effect Continues to Drive Profitable Growth for Uber
-
Undervalued by 28%, This Stock Is a Buy for Patient Investors
-
10 Best Growth Stocks to Buy for the Long Term
-
The Best Technology Stocks to Buy
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?
-
Disney Earnings: Improved Streaming Results Come at the Expense of Continued Linear Weakness
-
Apple: We Expect New Models and New Chip to Spur Return to iPad Growth
-
Palantir Earnings: AI Platform Drives Strong Start to 2024